Regencell Bioscience Holdings Limited
Market Cap
$11.36B
P/E Ratio
-2297.00
EPS
$-0.01
Dividend Yield
0.00%
52-Week Range
$0.53 — $83.60
Volume
56.52K
Avg Volume
462.15K
Beta
2.07
P/E (TTM)
-2297.00
Forward P/E
—
PEG Ratio
-35.73
P/S (TTM)
0.00
P/B (TTM)
2635.09
P/FCF
0.00
EV/EBITDA
-4867.80x
EV/Sales
—
ROE (TTM)
-0.62%
ROA (TTM)
-0.62%
ROIC
-0.35%
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
0.00%
Debt/Equity
0.11
Current Ratio
7.39
EPS Growth (YoY)
+0.35%
Revenue Growth (YoY)
—
EPS Growth (3Y)
—
EPS Growth (5Y)
—
Sales Growth (3Y)
—
Sales Growth (5Y)
—
EPS Est (This Year)
—
EPS Est (Next Year)
—
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.01
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
494.49M
Float
18.43M
Free Float %
3.73%
RSI (14)
53.37
SMA 20
$28.59
SMA 50
$25.02
SMA 200
$19.14
ATR (14)
4.81
Volatility (Week)
0.07%
Volatility (Month)
0.14%
Pattern
—
1 Day
-3.75%
1 Week
-6.22%
1 Month
-41.73%
3 Months
+104.92%
6 Months
+97.34%
1 Year
—
YTD
+29.89%
All-Time High
$83.60
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
HK
Exchange
NASDAQ
IPO Date
2021-07-16
Employees
12
CEO
Yat-Gai Au
Index Membership
—
Website
https://www.regencellbioscience.com
Regencell Bioscience Holdings Limited (RGC) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $11.36B, a P/E ratio of -2297.00, RGC is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare RGC against other stocks using dozens of fundamental and technical filters.
Regencell Bioscience Holdings Limited (RGC) has a trailing twelve-month (TTM) P/E ratio of -2297.00. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Regencell Bioscience Holdings Limited (RGC) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Regencell Bioscience Holdings Limited (RGC) has a market capitalization of $11.36 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Regencell Bioscience Holdings Limited (RGC) has returned +29.89% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.